C402-CD19-CAR

N/A

Report date: 2025/03/24 16:34:41

Base Information

Drug NameC402-CD19-CAR
Drug Alias NameC402-CD19-CAR
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacementsImmunologic cytotoxicity
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Exiuma Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Exiuma Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A